AGIOS PHARMACEUTICALS, INC.
AGIO · XNASCIK 1439222fmd_0JNRMNHS5GHWQP59NDS2JS6MPWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 70 | 43 | 94 | 118 | 0 | 0 | 14 | 27 | 36 | 54 |
| Cost of revenue | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 3 | 4 | 6 |
| Gross profit | 70 | 43 | 93 | 117 | 0 | 0 | 13 | 24 | 32 | 48 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Research and development | 220 | 293 | 341 | 214 | 221 | 257 | 280 | 296 | 301 | 340 |
| Selling, general and administrative | 51 | 71 | 114 | 102 | 115 | 121 | 122 | 120 | 157 | 180 |
| Total operating expenses | 271 | 364 | 457 | – | – | – | – | – | – | – |
| Operating income | (201) | (321) | (362) | (316) | (336) | (378) | (389) | (391) | (426) | (472) |
| Interest and investment income | 3 | 6 | 16 | 15 | 7 | 1 | 13 | – | – | – |
| Other non-operating income (expense) | – | – | – | 0 | 0 | 14 | 7 | 6 | 6 | 2 |
| Income before taxes | (198) | (315) | (346) | (301) | (329) | (357) | (232) | (352) | 718 | (414) |
| Income tax expense | 0 | 0 | 0 | 0 | – | – | 0 | 0 | 44 | (1) |
| Net income from continuing operations | (198) | (315) | (346) | (301) | (329) | (357) | (232) | (352) | 674 | (413) |
| Net income | (198) | (315) | (346) | (411) | (327) | 1,605 | (232) | (352) | 674 | (413) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |